Ignite Creation Date:
2024-05-05 @ 4:41 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00298636
Status:
COMPLETED
Last Update Posted:
2006-08-02
First Post:
2006-02-28
Brief Title:
Dose-Response of Adenosine for Perioperative Pain
Sponsor:
Xsira Pharmaceuticals
Organization:
Xsira Pharmaceuticals
Study Overview
Official Title:
A Phase 2 Randomized Double-Blind Placebo-Controlled Escalating Dose-Response Trial of Intravenous Adenosine for Perioperative Analgesia in Females Undergoing Abdominal Hysterectomy or Myomectomy
Status:
COMPLETED
Status Verified Date:
2006-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Adenosine A1 and A2 receptors are widely distributed in the brain and spinal cord and represent a non-opiate target for pain management Activated spinal A1 receptors inhibit sensory transmission by inhibiting the slow ventral root potential which is the C-fiber-evoked excitatory response associated with nociception Adenosine may inhibit intrinsic neurons through an increase in K conductance and presynaptic inhibition of sensory nerve terminals to inhibit the release of substance P and perhaps glutamate Although adenosine A3 receptors are not found in the nervous system adenosine is also known to have anti-inflammatory properties that may contribute to pain relief in the peripheral setting of inflammation
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None